ADMA Biologics Inc (ADMA NASDAQ) stock market data APIs
$21.3752
-0.09(-0.4%)
as of April 17, 2025
ADMA Biologics Inc Financial Data Overview
ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB, a human polyclonal antibody product for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It also develops a pipeline of plasma-derived therapeutics comprising products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, the company operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.
Prev. Close
21.3752
Open
21.2868
High
21.4408
Low
20.5143
52 wk Range
6.19-23.64
Market Cap
5 084 M
P/E Ratio
26.3086
Shares Outstanding
239 M
Revenue
426 M
EPS
0.136
Beta
0.526
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get ADMA Biologics Inc data using free add-ons & libraries
Get ADMA Biologics Inc Fundamental Data
ADMA Biologics Inc Fundamental data includes:
- Net Revenue: 426 M
- EBITDA: 147 M
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-02-26
- EPS/Forecast: 0.145
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
ADMA Biologics Inc News
New
ADMA Biologics (ADMA): Among Louis Navellier’s New Stock Picks
We recently published a list of Louis Navellier’s 10 New Stock Picks. In this article, we are going to take a look at where ADMA Biologics, Inc. (NASDAQ:ADMA) stands against other Louis Navellier’...
Why ADMA Biologics, Inc. (ADMA) Skyrocketed On Tuesday?
We recently published a list of 10 Firms End Stronger on Tuesday. In this article, we are going to take a look at where ADMA Biologics, Inc. (NASDAQ:ADMA) stands against other firms that end stronger...
Why ADMA Biologics Inc. (ADMA) Skyrocketed On Monday?
We recently published a list of Biotech Stocks Dominate Monday’s Top 10 Gainers. In this article, we are going to take a look at where ADMA Biologics Inc. (NASDAQ:ADMA) stands against other biotech ...
ADMA Biologics Statement on Tariffs
RAMSEY, N.J. and BOCA RATON, Fla., April 07, 2025 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedica...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
